Operates the world’s largest and most engaged digital diabetes community and provides data-driven and evidence-based digital health interventions for the remission of type 2 diabetes, prediabetes, and metabolic syndrome.
The DDM community welcomes over 3m visitors a month, with an organic social reach of 50 million and over 1.1m registered members across the platform, including 50,000 healthcare professionals. DDM has created a unique and powerful AI-driven technology platform to collect and analyse the big data generated through the community and uses this to create an expanding portfolio of clinically proven, evidence-based digital media health interventions that are scalable, engaging and effective. DDM has three interventions in the marketplace: the Hypo Program, Type 2 Testing Program and award-winning Low Carb Program.
In 2018, the Low Carb Program secured QISMET and CE accreditation, meeting all requirements for delivery within the NHS. A three-year study into the Low Carb Program is currently following 1,000 patients, with one-year outcomes published in JMIR Diabetes, an industry-leading diabetes journal.
Published outcomes demonstrate a 71% retention at one year with an average HbA1c reduction of 1.2% (13 mmol/mol) and one in four patients placing their type 2 diabetes into remission.
Over 375,000 people have used the Low Carb Program’s personalised structured education and ongoing support to help them improve type 2 diabetes and prediabetes control. Delivered across web, mobile apps and integrated with health and wearable devices, the Low Carb Program is sold directly to the consumer on a subscription basis and made available for a prescription through the NHS and other health authorities on a per-user, per year subscription basis.
In addition to the Low Carb Program, DDM operates other programs with global pharmaceutical and health care device partners and has plans to deliver a multitude of additional complimentary data-driven programs, products and services.
DDM is keen to hear from governments, insurers, pharmaceutical and healthcare organisations about partnering and licensing our products and services.
Products: Diabetes, digital health, healthcare, patient support, digital therapeutics, health data, type 2, low carb, HbA1c, education.